GlassScriptPhysician profile
Merin Joseph
NPI 1831620285
$10,758.26
in general payments reported to CMS, 2019-2025
41 companies · $1,764 in 2025
The $1,764 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,313 · 2022: $2,849 · 2023: $2,299 · 2024: $1,532 · 2025: $1,764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,636 · Long Term Medical Supply Or Device Loan: $960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,636.05 |
| Long Term Medical Supply Or Device Loan | $960.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $2,963.33 | 2021-2023 | Venacure 1470 Pro |
| Abbott Laboratories | $1,164.00 | 2021-2025 | Confirm Rx, Jot Dx, Cardiomems |
| Amgen INC. | $828.93 | 2021-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $727.27 | 2022-2025 | Watchman Flx, Resonate El Icd Vr, Watchman Access System |
| Novartis Pharmaceuticals Corporation | $563.34 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $553.05 | 2021-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $547.99 | 2022-2025 | Verquvo |
| Esperion Therapeutics, INC. | $355.12 | 2021-2025 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $250.92 | 2021-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $248.85 | 2021-2025 | Lifevest |
| Tactile Systems Technology INC | $237.73 | 2021-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Astrazeneca Pharmaceuticals LP | $216.86 | 2021-2025 | Farxiga, Wainua |
| Astellas Pharma US INC | $198.00 | 2021 | |
| Impulse Dynamics (USA) INC. | $193.29 | 2021-2023 | Optimizer |
| Novo Nordisk INC | $191.49 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $145.17 | 2021-2023 | |
| Actelion Pharmaceuticals US, INC. | $137.79 | 2024-2025 | Uptravi, Opsumit |
| Edwards Lifesciences Corporation | $121.08 | 2022-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Medtronic, INC. | $120.66 | 2022-2025 | Corevalve Evolut R, Venaseal, Symplicity G3 |
| Arbor Pharmaceuticals, INC. | $104.78 | 2021-2022 | |
| Baxter Healthcare | $101.46 | 2024-2025 | Hillrom - Carnation Ambulatory Monitor |
| Inspire Medical Systems, INC. | $91.25 | 2023-2025 | Inspire |
| Kestra Medical Technology Services, INC. | $81.74 | 2024 | Assure Wcd |
| Azurity Pharmaceuticals, INC. | $76.28 | 2023-2025 | Edarbyclor, Edarbi, Horizant |
| Pfizer INC. | $73.61 | 2023-2025 | |
| Cvrx, INC. | $63.88 | 2023-2024 | Barostim Neo System |
| Abiomed | $53.90 | 2025 | |
| Scpharmaceuticals INC. | $42.24 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.54 | 2022-2024 | Jardiance |
| Amarin Pharma, INC. | $37.15 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $34.41 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $27.52 | 2024 | Arcalyst |
| Medicomp INC | $24.50 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $24.34 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.09 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $18.29 | 2022 | |
| Preventice Services, LLC | $18.00 | 2021 | |
| Itamar Medical INC | $17.16 | 2023 | Watchpatone |
| Atricure, INC. | $15.76 | 2022 | |
| Glaxosmithkline, LLC. | $15.71 | 2025 | Shingrix, Arexvy |
| Cashflow Solutions, LLC | $12.78 | 2023 | Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Merin Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.